title: Multicenter evaluation of a commercial multiplex polymerase chain reaction test for screening plasma donations for parvovirus B19 DNA and hepatitis A virus RNA.
abstract: BACKGROUND
  Three European laboratories evaluated the TaqScreen DPX test (DPX test), a multiplex nucleic acid test assay for the simultaneous detection and quantitation of parvovirus B19 (B19V) DNA and the detection of hepatitis A virus (HAV) RNA.
  
  
  METHODS
  The 95% limit of detection of the test for B19V and HAV was determined using the respective WHO International Standards. The reproducibility of the test was evaluated by testing replicate samples of B19V at log 4.0 and 40 IU/mL and HAV at 5 IU/mL. The accuracy of the DPX test for B19V was evaluated by replicate testing of B19V samples containing log 3.0, log 4.0, and log 5.0 IU/mL. Panels of B19V Genotypes 1, 2, and 3 and HAV genotypes were evaluated. Cross-contamination was evaluated. For comparison of the DPX test and the established tests, the sites tested plasma samples in pools of either 96 or 480 donations.
  
  
  RESULTS
  The mean 95% lower limits of detection of the three laboratories for B19V and HAV were 20.30 and 1.85 IU/mL. The test showed good reproducibility with the major part of the variance of the test being attributed to intermediate assay variation. The test showed great accuracy for B19V, especially at log 4.0 IU/mL. Spiking of test pools of 480 donations and manufacturing pools with log 4.0 IU/mL B19 DNA and 4 IU/mL HAV RNA showed that the DPX assay was robust. The test was able to detect the three genotypes of B19V and HAV genotypes. No cross-contamination was seen. Test results of routine samples correlated well with those of the established tests.
  
  
  CONCLUSIONS
  The DPX test is a robust and sensitive test for the detection of B19V and HAV in plasma samples. The quantitative B19V results obtained with the test are accurate, and the test is able to detect all the known genotypes of B19V and HAV and fulfills all the European Pharmacopoeia and Food and Drug Administration requirements for a B19V and HAV test for screening of plasma donations and samples from plasma pools for manufacture.
authors.affiliation: Department of Viral Serology, Sanquin Blood Supply Foundation, Amsterdam, the Netherlands. m.koppelman@sanquin.nl
authors.forename: Marco H G M
authors.initials: MH
authors.lastname: Koppelman
authors.forename: H Theo M
authors.initials: HT
authors.lastname: Cuijpers
authors.forename: Susanna
authors.initials: S
authors.lastname: Wessberg
authors.forename: Anne
authors.initials: A
authors.lastname: Valkeajärvi
authors.forename: Lutz
authors.initials: L
authors.lastname: Pichl
authors.forename: Volkmar
authors.initials: V
authors.lastname: Schottstedt
authors.forename: John
authors.initials: J
authors.lastname: Saldanha
mesh_terms: D001782:Blood Donors; D004279:DNA, Viral / Q000097:blood / Q000235:genetics; D046148:Donor Selection / Q000379:methods / Q000592:standards; D030041:Hepatitis A virus / Q000235:genetics*; D006801:Humans; D016732:Parvovirus B19, Human / Q000235:genetics*; D016133:Polymerase Chain Reaction / Q000379:methods / Q000592:standards; D012367:RNA, Viral / Q000097:blood / Q000235:genetics; D012680:Sensitivity and Specificity; D014481:United States; D014486:United States Food and Drug Administration; D014944:World Health Organization
chemical_list: D004279:DNA, Viral; D012367:RNA, Viral